Jeremy Whitaker
Analyst · Nicusa
Thank you, Kurt. Turning to our financial results for the 3 and 9 months ended March 31, 2012. Net revenue for the 3 months ended March 31, 2012 was $12.1 million, a decrease of 2% compared to $12.4 million for the 3 months ended March 31, 2011. And sequentially, an increase in 16% compared to $10.5 million for the 3months ended December 31, 2011.
The year-over-year decrease was due to lower sales of external device enablement and device management products. The sequential increase in that revenue was primarily due to a $1.1 million increase in our device enablement product line as a result of a recovery in embedded sales in our EMEA and America’s regions, and a $0.6 million increase in our device management product line, the majority of which were the result of sales from the xPrintServer Network Edition which we began taking preorders on December 13, 2011.
For the 9 months ended March 31, 2012 net revenues were $33.8 million compared to $37.3 million for the 9 months ended March 31, 2011. Gross profit as a percentage of net revenue for the 3 months ended March 31, 2012, was 48.8% compared to 51.4% for the 3 months ended March 31, 2011 and 48.2% for the 3 months ended December 31, 2011.
With 3 sequential quarters of margin improvement, we believe that we have made significant progress towards brining margins back in line with our corporate target of 49 to 51%.
Gross profit as a percentage of net revenue for the 9 months ended March 31, 2012, was 48.2% compared to 50.6% for the 9 months ended March 31, 2011. GAAP operating expenses were $5.9 million for the 3 months ended March 31, 2012, a decrease of $0.8 million or 12% compared to $6.7 million for the 3 months ended March 31, 2011, and down sequentially by $0.5 million for 7% from $6.4 million for the 3 months ended December 31, 2011.
GAAP operating expenses for the 9 months ended March 31, 2012 were $18.9 million compared to $20.4 million for the 9 months ended March 31, 2011.
Selling, general, and administrative expenses were $4.1 million for the 3 months ended March 31, 2012, a decrease of $0.9 million of 17% compared to $4.9 million for the 3 months ended March 31, 2011, and down sequentially by $0.4 million or 8% from $4.4 million for the 3 months ended December 31, 2011.
This marked the third quarter in a row that we reduced SG&A expenses. For the 9 months ended March 31, 2012, selling, general, and administrative expenses were $13.5 million compared to $15.1 million for the 9 months ended March 31, 2011.
Research and development expenses were $1.8 million for the 3 months ended March 31, 2012, which was flat compared with 3 months ended March 31, 2011, and a slight increase from $1.6 million for the 3 months ended December 31, 2011.
R&D expenses for the 3 months ended March 31, 2012, increased slightly due to costs associated with new product launches. For the 9 months ended March 31, 2012, R&D expenses were $5.1 million compared to $5.3 million for the 9 months March 31, 2011.
Non-GAAP operating expenses were $5.6 million for the 3 months ended March 31, 2012 compared to $5.8 million for the 3 months ended March 31, 2011. The $5.8 million for the 3 months ended December 31, 2011.
For the 9 months ended March 31, 2012, non-GAAP operating expenses were $17.5 million, flat with $17.5 million for the 9 months ended March 31, 2011.
We may see a slight increase in operating expenses moving forward as we continue to execute on our product development strategy. Assuming a 50% gross margin, we still expect to maintain a quarterly non-GAAP breakeven point at or below $11 million in quarterly net revenue.
GAAP net loss was $41,000 for the 3 months ended March 31, 2012 or $0.00 per share compared to a GAAP net loss of $399,000 or $0.04 per share for the 3 months ended March 31, 2011, and sequentially a GAAP net loss of $1.4 million or $0.13 per share the 3 months ended December 31, 2011.
GAAP net loss for the 9 months ended March 31, 2012, was $2.9 million or $0.27 per share compared to a GAAP net loss of $1.7 million or $0.16 per share for the 9 months ended March 31, 2011.
Non-GAAP net income for the 3 months ended March 31, 2012, was $471,000 or $0.04 per share compared to non-GAAP net income of $691,000 or $0.06 per share for the 3 months ended March 31, 2011, and sequentially a non-GAAP net loss of $629,000 or $0.06 per share for the 3 months ended December 31, 2011.
Non-GAAP net loss for the 9 months ended March 31, 2012, was $855,000 or $0.08 per share compared to non-GAAP net income of $1.7 million or $0.16 per share for the 9 months ended March 31, 2011.
Now turning to the balance sheet. Cash and cash equivalence as of March 31, 2012 were $1.8 million compared to $5.8 million as of June 30, 2011.
As previously mentioned by Kurt, we completed 2 capital transactions in April and May 2012, generating a total of approximately $9.3 million in net proceeds which we believe will strengthen our working capital position.
Accounts receivable as of March 31, 2012 were $2.7 million compared to $1.4 million as of December 31, 2011 and $2.9 million as of June 30, 2011. The sequential increase in accounts receivable was due to the sequential increase in net revenue of 16% and the timing of product shipments, which were more heavily weighted towards a second half of the March 2012 quarter.
We are beginning to see results from our inventory management efforts which resulted in a reduction of our net inventories to $6.8 million as of March 31, 2012, a decrease of $2.4 million or 26% compared to 9.2 million as of June 30, 2011.
While we will continue to optimize our inventory levels, we do not expect to see such dramatic decreases in inventory going forward. And in fact, we could see some decreases in inventories as we put in place stocking levels for product releases and increased demand.
Accounts payable were $4.4 million as of March 31, 2012, a decrease of $3.9 million or 47% compared to $8.4 million as of June 30, 2011.
Working capital was $2.4 million as of March 31, 2012, compared to $2.4 million as of December 31, 2011, and $5.2 million as of June 30, 2011.
The restructuring plan, costs containment measures and inventory reduction initiated by management during the quarter ended December 31, 2011 were instrumental in stabilizing our working capital during the March, 2012 quarter. While stabilizing working capital was a key part of our short-term strategy, it is just as critical for us to have sufficient working capital to execute on our growth strategy. For example, we were supply constrained during the March 2012 quarter, in large part due to insufficient working capital. Our recent fundraising generated an additional cash of $9.3 million and we believe that for the foreseeable future it will provide us with the capital required to execute on our strategy and achieve profitable growth.
I’ll now turn the call back to Kurt.